Related Experiment Videos
Effects of long-term treatment with simvastatin on some hemostatic parameters in continuous ambulatory peritoneal
J Małyszko1, J S Małyszko, T Hryszko
1Department of Nephrology and Internal Medicine, Medical School, PL-15-540 Białystok, Zurawia 14, Poland. jolmal@poczta.snet.pl
Insights
Simvastatin effectively lowers lipids and improves platelet function and endothelial health in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). This statin therapy offers benefits for cardiovascular risk factors in this high-risk population.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Uremia frequently causes lipid, hemostasis, and platelet function disturbances, increasing atherosclerosis and thrombotic risks.
- Continuous ambulatory peritoneal dialysis (CAPD) patients have high risks of dyslipidemia and cardiovascular death.
- Statins show promise in improving lipid profiles and hemostasis in uremic patients.
Purpose of the Study:
- To evaluate the effects of simvastatin on platelet functions, hemostatic parameters, and serum lipids in hyperlipidemic CAPD patients.
- To assess changes over a 6-month treatment period.
Main Methods:
- Eight hyperlipidemic CAPD patients received 10 mg of simvastatin daily.
- Platelet aggregation was measured in whole blood and platelet-rich plasma (PRP) using collagen, arachidonic acid, ADP, and ristocetin.
- Serum lipids, P-selectin, fibrinolytic activity index, thrombomodulin, and prothrombin fragments 1+2 were also assessed at baseline and after 1, 3, and 6 months.
Main Results:
- Simvastatin significantly reduced whole-blood and PRP platelet aggregation induced by collagen and ADP, and ristocetin-induced aggregation in PRP.
- Significant improvements were observed in fibrinolytic activity and reduced thrombomodulin levels, indicating better endothelial function.
- Cholesterol and LDL levels decreased significantly within 1 month and remained low throughout the study.
Conclusions:
- Simvastatin is an effective hypolipidemic agent in CAPD patients.
- The therapy favorably impacts platelet aggregation, endothelial function, and fibrinolysis.
- Simvastatin may help mitigate cardiovascular risks in this patient population.
Background/Aim:
Disturbances in serum lipids, hemostasis and platelet functions are frequent features in uremia and may contribute to the progression of atherosclerosis and its thrombotic complications. Recently, attention has been paid to beneficial effects of statins on serum lipids and hemostasis in uremic patients. Peritoneally dialyzed (continuous ambulatory peritoneal dialysis; CAPD) subjects are particularly prone to dyslipidemia and have a high risk of cardiovascular death. The purpose of this work was to assess platelet functions, some hemostatic parameters and serum lipids in 8 hyperlipidemic CAPD patients treated with simvastatin (Zocor, MSD) for 6 months.
Methods:
Platelet aggregation in whole blood and in platelet-rich plasma (PRP) induced by collagen (2 microg/ml for whole blood and PRP), arachidonic acid (0.75 mM for whole blood and PRP), ADP (10 microM for whole blood and 5 microM for PRP) and ristocetin (0.75 mg/ml for whole blood and 1.5 mg/ml for PRP) was studied before and after 1, 3 and 6 months of simvastatin (dose: 10 mg at bedtime) treatment.
Results:
Whole-blood platelet aggregation induced by collagen decreased significantly after 3 and 6 months of the therapy, whereas in PRP, platelet aggregation induced by collagen and ADP decreased significantly after 6 months. Ristocetin-induced platelet aggregation in PRP decreased significantly after 3 and 6 months of simvastatin therapy. P-selectin remained unaltered by 6 months of simvastatin therapy. The fibrinolytic activity index was significantly higher after 3 months of the therapy when compared to the baseline values. Thrombomodulin, a marker of endothelial cell injury, was significantly lower after 3 and 6 months of the therapy. Prothrombin fragments 1 + 2 did not change significantly during 6 months of simvastatin administration. Cholesterol and LDL fell significantly as early as after 1 month and remained lowered during further months of the therapy.
Conclusion:
Simvastatin is an effective hypolipemic agent and favorably affects platelet aggregation, endothelial function and fibrinolysis in CAPD patients.